Skip to main content
Premium Trial:

Request an Annual Quote

Rain Therapeutics, Tempus Partner to Identify Patients with MDM2-Amplified Tumors for Basket Trial

NEW YORK – Rain Therapeutics said on Thursday it has inked an agreement with Tempus, under which the Chicago-based firm will provide testing and patient matching services for Rain's Phase II tumor-agnostic basket trial for its investigational drug RAIN-32.

Tempus will provide centralized tumor testing and patient matching services through its Connect & TIME Trial Network platform. Specifically, it will evaluate patients with solid tumors for pre-specified MDM2 amplification levels and normal p53 status using its DNA- and RNA-based tumor sequencing tests, Tempus xT and Tempus xE, as well as conduct comprehensive tumor profiling to determine if they are eligible to receive Rain's MDM2 inhibitor RAIN-32 within the Phase II basket trial.

Earlier this week, Rain announced a similar partnership with Caris Life Sciences for this same study. Caris is providing whole-exome and -transcriptome sequencing services to help Rain identify patients eligible for the trial slated to begin in the second half of 2021.

The Newark, California-based company licensed RAIN-32, previously called milademetan, from Daiichi Sankyo in September. The firm is also planning two other trials of the drug, a Phase III study in MDM2-amplified liposarcoma and a Phase II trial in intimal sarcoma.

RAIN-32 showed activity in both MDM2-amplified liposarcoma and solid tumors in a Phase I trial presented last year. In patients with liposarcoma the disease control rate was 58.5 percent, and among patients with non-liposarcoma solid tumors the disease control rate was 32.4 percent.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.